Ids
stringlengths 36
36
| text
stringlengths 45
2.03k
| label
int64 0
1
|
|---|---|---|
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Diagnostic (FLT PET) secondary trial: Arm A All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Diagnostic (FLT PET) secondary trial: Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. lapatinib ditosylate: Given PO and capecitabine: Given PO All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Diagnostic (FLT PET) secondary trial: Arm B All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Diagnostic (FLT PET) secondary trial: Patients receive capecitabine and lapatinib ditosylate as in arm I. Patients also receive cixutumumab IV over 1-1½ hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV, lapatinib ditosylate: Given PO and capecitabine: Given PO All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Patients with early stage, ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment. The surgery follows 1-7 days after the second FLT PET scan. secondary trial: Arm A All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Patients with early stage, ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment. The surgery follows 1-7 days after the second FLT PET scan. secondary trial: Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. lapatinib ditosylate: Given PO and capecitabine: Given PO All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Patients with early stage, ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment. The surgery follows 1-7 days after the second FLT PET scan. secondary trial: Arm B All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Patients with early stage, ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment. The surgery follows 1-7 days after the second FLT PET scan. secondary trial: Patients receive capecitabine and lapatinib ditosylate as in arm I. Patients also receive cixutumumab IV over 1-1½ hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV, lapatinib ditosylate: Given PO and capecitabine: Given PO All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Tracer used in the FLT PET (positron emission tomography) scanning procedure: [F18] fluorothymidine. secondary trial: Arm A All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Tracer used in the FLT PET (positron emission tomography) scanning procedure: [F18] fluorothymidine. secondary trial: Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. lapatinib ditosylate: Given PO and capecitabine: Given PO All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Tracer used in the FLT PET (positron emission tomography) scanning procedure: [F18] fluorothymidine. secondary trial: Arm B All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Tracer used in the FLT PET (positron emission tomography) scanning procedure: [F18] fluorothymidine. secondary trial: Patients receive capecitabine and lapatinib ditosylate as in arm I. Patients also receive cixutumumab IV over 1-1½ hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV, lapatinib ditosylate: Given PO and capecitabine: Given PO All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Positron Emission Tomography: Undergo FLT PET secondary trial: Arm A All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Positron Emission Tomography: Undergo FLT PET secondary trial: Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. lapatinib ditosylate: Given PO and capecitabine: Given PO All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Positron Emission Tomography: Undergo FLT PET secondary trial: Arm B All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Positron Emission Tomography: Undergo FLT PET secondary trial: Patients receive capecitabine and lapatinib ditosylate as in arm I. Patients also receive cixutumumab IV over 1-1½ hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV, lapatinib ditosylate: Given PO and capecitabine: Given PO All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Laboratory Biomarker Analysis: Correlative studies - Ki67 staining of the tumor tissue in the biopsy and surgical specimen. secondary trial: Arm A All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Laboratory Biomarker Analysis: Correlative studies - Ki67 staining of the tumor tissue in the biopsy and surgical specimen. secondary trial: Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. lapatinib ditosylate: Given PO and capecitabine: Given PO All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Laboratory Biomarker Analysis: Correlative studies - Ki67 staining of the tumor tissue in the biopsy and surgical specimen. secondary trial: Arm B All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
5bc844fc-e852-4270-bfaf-36ea9eface3d | primary trial: Laboratory Biomarker Analysis: Correlative studies - Ki67 staining of the tumor tissue in the biopsy and surgical specimen. secondary trial: Patients receive capecitabine and lapatinib ditosylate as in arm I. Patients also receive cixutumumab IV over 1-1½ hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV, lapatinib ditosylate: Given PO and capecitabine: Given PO All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Histologically or cytologically confirmed infiltrating breast cancer Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Clinical evidence of metastatic disease Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Measurable disease, defined as at lePatients with histologic confirmation of invasive breast carcinoma.ast one measurable lesion per RECIST criteria Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | No non-measurable disease only, defined as all other lesions, including small lesions (longest diameter < 2 cm) and truly non-measurable lesions, including any of the following: Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Bone lesions Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Leptomeningeal disease Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Ascites Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Pleural/pericardial effusion Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Inflammatory breast disease Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Lymphangitis cutis/pulmonis Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Abdominal masses that are not confirmed and followed by imaging techniques Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Cystic lesions Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Patients with HER-2/neu positive tumors, must have received prior treatment with trastuzumab (Herceptin®) or have a contraindication for trastuzumab Patients with Platelet count over 100,000/mm¬¨‚â•, ANC < 1,700/mm¬¨‚â• and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | No evidence of active brain metastasis, including leptomeningeal involvement, on MRI or CT scan Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | CNS metastasis controlled by prior surgery and/or radiotherapy allowed Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Must be asymptomatic for 2 months with no evidence of progression prior to study entry Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Hormone receptor status not specified Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | PATIENT CHARACTERISTICS: Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Menopausal status not specified Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Life expectancy 12 weeks Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | ECOG performance status 0-1 Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | ANC 1,500/mm³ Patients with Platelet count over 100,000/mm¬¨‚â•, ANC < 1,700/mm¬¨‚â• and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Platelet count 100,000/mm³ Patients with Platelet count over 100,000/mm¬¨‚â•, ANC < 1,700/mm¬¨‚â• and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Hemoglobin 9.0 g/dL Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | AST and ALT 2.5 times upper limit of normal (ULN) Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Alkaline phosphatase 2.5 times ULN Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Total bilirubin 1.5 times ULN Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Creatinine 1.5 mg/dL Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Urine protein:creatinine ratio < 1 or urinalysis < 1+ protein Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Patients discovered to have 1+ proteinuria at baseline must demonstrate 24-hour urine protein < 1 g Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Not pregnant or nursing Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Negative pregnancy test Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Fertile patients must use effective contraception during and for 30 days after completion of study therapy Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Able to complete questionnaires alone or with assistance Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | No peripheral neuropathy > grade 1 Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | No history of allergy or hypersensitivity to albumin-bound paclitaxel, paclitaxel, gemcitabine hydrochloride, bevacizumab, albumin, drug product excipients, or chemically similar agents Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | No stage III or IV invasive, non-breast malignancy within the past 5 years Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | No other active malignancy, except nonmelanoma skin cancer or carcinoma in situ of the cervix Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Patient must not be receiving other specific treatment for a prior malignancy Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | No uncontrolled hypertension (i.e., blood pressure [BP] > 160/90 mm Hg on 2 occasions at least 5 minutes apart) Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Patients who have recently started or adjusted antihypertensive medications are eligible providing that BP is < 140/90 mm Hg on any new regimen for 3 different observations in 14 days Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | No bleeding diathesis or uncontrolled coagulopathy Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | No hemoptysis within the past 6 months Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | No prior arterial or venous thrombosis within the past 12 months Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | No history of cerebrovascular accident Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | No history of hypertensive crisis or hypertensive encephalopathy Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | No abdominal fistula or gastrointestinal perforation within the past 6 months Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | No serious non-healing wound, ulcer, or fracture Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | No clinically significant cardiac disease, defined as any of the following: Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Congestive heart failure Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Symptomatic coronary artery disease Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Unstable angina Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Cardiac arrhythmias not well controlled with medication Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Myocardial infarction within the past 12 months Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | No comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for study entry or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | PRIOR CONCURRENT THERAPY: Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | See Disease Characteristics Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | No prior chemotherapy for metastatic disease Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | May have received one prior adjuvant chemotherapy regimen Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Prior neoadjuvant chemotherapy allowed Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | More than 6 months since prior adjuvant or neoadjuvant taxane (i.e., docetaxel or paclitaxel) therapy Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Prior hormonal therapy in either adjuvant or metastatic setting allowed Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | More than 4 weeks since prior radiotherapy (except if to a non-target lesion only, or single dose radiation for palliation) Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Prior radiotherapy to a target lesion is allowed provided there has been clear progression of the lesion since radiotherapy was completed Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | More than 4 weeks since prior cytotoxic chemotherapeutic agent or investigational drug Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | More than 2 weeks since prior and no concurrent acetylsalicylic acid, anticoagulants, or thrombolytic agents (except for once-daily 81 mg acetylsalicylic acid) Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | More than 6 weeks since prior major surgery, chemotherapy, or immunologic therapy Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | More than 1 week since prior minor surgery (e.g., core biopsy) Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Placement of a vascular access device within 7 days is allowed Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | More than 3 months since prior neurosurgery Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | No concurrent treatment in a different clinical study in which investigational procedures are performed or investigational therapies are administered Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
86b7cb3d-6186-4a04-9aa6-b174ab764eed | Trials related to symptom management (Cancer Control) which do not employ hormonal treatments or treatments that may block the path of the targeted agents used in this study may be allowed Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | 0 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Total: 285/752 (37.90%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Anaemia 2/752 (0.27%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Disseminated intravascular coagulation 2/752 (0.27%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Febrile neutropenia 51/752 (6.78%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Neutropenia 47/752 (6.25%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Thrombocytopenia 2/752 (0.27%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Atrial fibrillation 1/752 (0.13%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Atrial flutter 0/752 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |